|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
DE741187T1
(de)
*
|
1995-05-05 |
1997-04-30 |
Hoffmann La Roche |
Rekombinante Obesitäts-(OB)-Proteine
|
|
DK0866720T3
(da)
*
|
1995-11-22 |
2004-06-14 |
Amgen Inc |
OB-protein til forögelse af mager kropsmasse
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US6025324A
(en)
*
|
1996-05-15 |
2000-02-15 |
Hoffmann-La Roche Inc. |
Pegylated obese (ob) protein compositions
|
|
PT954588E
(pt)
*
|
1996-12-20 |
2007-03-30 |
Amgen Inc |
Composições que contêm uma proteína de fusão ob e métodos para a sua preparação e utilização
|
|
AU770897B2
(en)
*
|
1996-12-20 |
2004-03-04 |
Amgen, Inc. |
OB fusion protein compositions and methods
|
|
WO1998046257A1
(en)
*
|
1997-04-17 |
1998-10-22 |
Amgen Inc. |
Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
|
|
AU2002300605B8
(en)
*
|
1997-04-17 |
2006-02-09 |
Amgen Inc. |
Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
|
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
|
ATE267215T1
(de)
|
1997-12-08 |
2004-06-15 |
Lexigen Pharm Corp |
Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
|
|
WO1999054360A1
(en)
|
1998-04-23 |
1999-10-28 |
Ajinomoto Co., Inc. |
Substance with antithrombotic activity and method for detecting glycokallidin
|
|
US6492138B1
(en)
|
1998-05-21 |
2002-12-10 |
Amgen Canada Inc. |
Polynucleotides encoding a novel SHC-binding protein
|
|
US6420339B1
(en)
*
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
PL202058B1
(pl)
|
1999-08-09 |
2009-05-29 |
Merck Patent Gmbh |
Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
|
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
|
AU4314801A
(en)
|
2000-02-11 |
2001-08-20 |
Lexigen Pharm Corp |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
SK982003A3
(en)
|
2000-06-29 |
2004-05-04 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
US6962903B2
(en)
*
|
2001-02-21 |
2005-11-08 |
Alavita, Inc. |
Modified annexin proteins and methods for preventing thrombosis
|
|
US7635680B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaceuticals, Inc. |
Attenuation of reperfusion injury
|
|
US7645739B2
(en)
|
2001-02-21 |
2010-01-12 |
Alavita Pharmaceuticals, Inc. |
Modified annexin compositions and methods of using same
|
|
US7635676B2
(en)
|
2001-02-21 |
2009-12-22 |
Alavita Pharmaccuticals, Inc. |
Modified annexin proteins and methods for their use in organ transplantation
|
|
US7148321B2
(en)
|
2001-03-07 |
2006-12-12 |
Emd Lexigen Research Center Corp. |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
US6992174B2
(en)
|
2001-03-30 |
2006-01-31 |
Emd Lexigen Research Center Corp. |
Reducing the immunogenicity of fusion proteins
|
|
US6969517B2
(en)
|
2001-05-03 |
2005-11-29 |
Emd Lexigen Research Center Corp. |
Recombinant tumor specific antibody and use thereof
|
|
ATE542137T1
(de)
|
2001-12-04 |
2012-02-15 |
Merck Patent Gmbh |
Immunocytokine mit modulierter selektivität
|
|
KR101086660B1
(ko)
|
2002-12-17 |
2011-11-24 |
메르크 파텐트 게엠베하 |
Ｇｄ2 에 결합하는 마우스 14.18 항체의 인간화 항체(ｈ14.18) 및 그것의 ｉｌ-2 와의 융합
|
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
NZ541365A
(en)
|
2002-12-27 |
2009-09-25 |
Diobex Inc |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
|
US20050176108A1
(en)
*
|
2003-03-13 |
2005-08-11 |
Young-Min Kim |
Physiologically active polypeptide conjugate having prolonged in vivo half-life
|
|
US7736653B2
(en)
*
|
2003-11-13 |
2010-06-15 |
Hanmi Pharm. Co., Ltd |
Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier
|
|
CN100467488C
(zh)
|
2003-12-30 |
2009-03-11 |
默克专利有限公司 |
Il-7融合蛋白
|
|
RU2370276C2
(ru)
|
2003-12-31 |
2009-10-20 |
Мерк Патент Гмбх |
Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
|
|
AU2005203962C1
(en)
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
KR100639397B1
(ko)
*
|
2004-03-18 |
2006-10-26 |
(주)에스제이바이오메드 |
항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
|
|
AU2005313492B2
(en)
|
2004-12-09 |
2011-12-15 |
Merck Patent Gmbh |
IL-7 variants with reduced immunogenicity
|
|
US8227408B2
(en)
|
2005-09-07 |
2012-07-24 |
Neurotez, Inc. |
Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
|
|
US8716220B2
(en)
|
2005-09-07 |
2014-05-06 |
Nikolaos Tezapsidis |
Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
|
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
|
KR20110028457A
(ko)
|
2008-05-21 |
2011-03-18 |
뉴로테즈 인코포레이티드 |
신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
|
|
KR20120030383A
(ko)
|
2009-04-22 |
2012-03-28 |
메르크 파텐트 게엠베하 |
변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
|
|
CN104147596A
(zh)
*
|
2013-05-14 |
2014-11-19 |
李荣秀 |
生物药非共价结合聚合物延长治疗浓度的方法及用途
|
|
CN104524568B
(zh)
*
|
2015-01-08 |
2018-04-20 |
中国人民解放军第二军医大学 |
一种治疗肥胖症的药物组合物及其应用
|